Paired Tissue-Liquid Biopsy Approach in Oncology Trials May Improve Enrollment and Molecular Profiling

A recent report highlights the potential benefits of using a paired tissue-liquid biopsy approach in oncology clinical trials. This method combines traditional tissue biopsies with liquid biopsies, which analyze circulating tumor DNA (ctDNA) found in plasma. The report suggests that this dual strategy could improve patient enrollment rates and enhance trial outcomes by providing more comprehensive molecular profiling.

The paired approach allows researchers to gather data from both solid tumor samples and blood-based biomarkers, offering a broader understanding of cancer biology. Liquid biopsies are less invasive than tissue biopsies, making them accessible to patients who may not be eligible for traditional sampling methods due to health concerns or logistical barriers. By incorporating liquid biopsies alongside tissue analysis, trials can potentially include a wider range of participants while maintaining robust data quality. The report emphasizes that this combined methodology could streamline recruitment processes and provide deeper insights into treatment efficacy and resistance mechanisms in oncology studies.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: December 1, 2025

Related posts:

14 Million Could Lose Health Coverage, Potentially Reversing ACA Gains Bill & Melinda Gates Foundation Commits $2.5 Billion to Women’s Health Initiatives Globally Study Identifies Role of ACSS1 in Mammary Gland Development and Lactation Study Explores DNA Methylation Changes During Colorectal Cancer Progression

Author

GOAI